These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
277 related articles for article (PubMed ID: 9869174)
1. von Willebrand factor (vWf) as a plasma marker of endothelial activation in diabetes: improved reliability with parallel determination of the vWf propeptide (vWf:AgII). Vischer UM; Emeis JJ; Bilo HJ; Stehouwer CD; Thomsen C; Rasmussen O; Hermansen K; Wollheim CB; Ingerslev J Thromb Haemost; 1998 Dec; 80(6):1002-7. PubMed ID: 9869174 [TBL] [Abstract][Full Text] [Related]
2. Acute von Willebrand factor secretion from the endothelium in vivo: assessment through plasma propeptide (vWf:AgII) Levels. Vischer UM; Ingerslev J; Wollheim CB; Mestries JC; Tsakiris DA; Haefeli WE; Kruithof EK Thromb Haemost; 1997 Feb; 77(2):387-93. PubMed ID: 9157601 [TBL] [Abstract][Full Text] [Related]
3. von Willebrand factor and its propeptide in children with diabetes. Relation between endothelial dysfunction and microalbuminuria. Verrotti A; Greco R; Basciani F; Morgese G; Chiarelli F Pediatr Res; 2003 Mar; 53(3):382-6. PubMed ID: 12595584 [TBL] [Abstract][Full Text] [Related]
4. Heterogeneous nature of microalbuminuria in NIDDM: studies of endothelial function and renal structure. Fioretto P; Stehouwer CD; Mauer M; Chiesura-Corona M; Brocco E; Carraro A; Bortoloso E; van Hinsbergh VW; Crepaldi G; Nosadini R Diabetologia; 1998 Feb; 41(2):233-6. PubMed ID: 9498659 [TBL] [Abstract][Full Text] [Related]
5. Hemorheology, plasma protein composition and von Willebrand factor in type I diabetic nephropathy. Zimmermann J; Schramm L; Wanner C; Mulzer E; Henrich HA; Langer R; Heidbreder E Clin Nephrol; 1996 Oct; 46(4):230-6. PubMed ID: 8905207 [TBL] [Abstract][Full Text] [Related]
7. Comparison between von Willebrand factor (VWF) and VWF antigen II in normal individuals and patients with von Willebrand disease. de Romeuf C; Mazurier C Thromb Haemost; 1998 Jul; 80(1):37-41. PubMed ID: 9684782 [TBL] [Abstract][Full Text] [Related]
8. Von Willebrand factor propeptide in vascular disorders. van Mourik JA; Romani de Wit T Thromb Haemost; 2001 Jul; 86(1):164-71. PubMed ID: 11487004 [TBL] [Abstract][Full Text] [Related]
9. Von Willebrand factor in type 1 diabetes: its production and coronary artery calcification. Chan NN; Fuller JH; Rubens M; Colhoun HM Med Sci Monit; 2003 Jul; 9(7):CR297-303. PubMed ID: 12883448 [TBL] [Abstract][Full Text] [Related]
10. Quantitative analysis of von Willebrand factor and its propeptide in plasma in acquired von Willebrand syndrome. van Genderen PJ; Boertjes RC; van Mourik JA Thromb Haemost; 1998 Sep; 80(3):495-8. PubMed ID: 9759633 [TBL] [Abstract][Full Text] [Related]
12. Biochemical markers of endothelial activation in primary hyperparathyroidism. Fallo F; Cella G; Casonato A; Ermani M; Vettor R; Zanella S; Lumachi F Horm Metab Res; 2006 Feb; 38(2):125-9. PubMed ID: 16523414 [TBL] [Abstract][Full Text] [Related]
13. Diabetes is associated with a high incidence of endothelial-binding antibodies which do not correlate with retinopathy, von Willebrand factor, angiotensin-converting enzyme or C-reactive protein. Petty RG; Pottinger BE; Greenwood RM; Pearson JD; Mahler RF Diabetes Res; 1991 Jul; 17(3):115-23. PubMed ID: 1668655 [TBL] [Abstract][Full Text] [Related]
15. Prognostic value of plasma soluble P-selectin and von Willebrand factor as indices of platelet activation and endothelial damage/dysfunction in high-risk patients with hypertension: a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial. Varughese GI; Patel JV; Tomson J; Blann AD; Hughes EA; Lip GY J Intern Med; 2007 Apr; 261(4):384-91. PubMed ID: 17391113 [TBL] [Abstract][Full Text] [Related]
16. Increased level of von Willebrand factor is significantly and independently associated with diabetes in postinfarction patients. THROMBO Investigators. Zareba W; Pancio G; Moss AJ; Kalaria VG; Marder VJ; Weiss HJ; Watelet LF; Sparks CE Thromb Haemost; 2001 Sep; 86(3):791-9. PubMed ID: 11583309 [TBL] [Abstract][Full Text] [Related]
17. Relations between von Willebrand factor, markers of oxidative stress and microalbuminuria in patients with type 2 diabetes mellitus. Ibrahim HA; El-Meligi AA; Abdel-Hamid M; Elhendy A Med Sci Monit; 2004 Mar; 10(3):CR85-9. PubMed ID: 14976459 [TBL] [Abstract][Full Text] [Related]
18. Decrease in von Willebrand factor levels after a high-monounsaturated-fat diet in non-insulin-dependent diabetic subjects. Rasmussen O; Thomsen C; Ingerslev J; Hermansen K Metabolism; 1994 Nov; 43(11):1406-9. PubMed ID: 7526126 [TBL] [Abstract][Full Text] [Related]
19. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. De Jager J; Kooy A; Lehert P; Bets D; Wulffelé MG; Teerlink T; Scheffer PG; Schalkwijk CG; Donker AJ; Stehouwer CD J Intern Med; 2005 Jan; 257(1):100-9. PubMed ID: 15606381 [TBL] [Abstract][Full Text] [Related]
20. Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: relationship to endothelial dysfunction and laser treatment. Lip PL; Belgore F; Blann AD; Hope-Ross MW; Gibson JM; Lip GY Invest Ophthalmol Vis Sci; 2000 Jul; 41(8):2115-9. PubMed ID: 10892852 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]